Get the Stockscreener App
18.04
11.50%
1.86
After Hours:
17.00
-1.04
-5.76%
Bicara Therapeutics Inc stock is traded at $18.04, with a volume of 778.49K.
It is up +11.50% in the last 24 hours and up +5.74% over the past month.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
See More
Previous Close:
$16.18
Open:
$16.13
24h Volume:
778.49K
Relative Volume:
1.31
Market Cap:
$988.27M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+22.06%
1M Performance:
+5.74%
6M Performance:
+23.65%
1Y Performance:
+1.52%
1-Day Range:
$15.83
$18.16
1-Week Range:
$14.62
$18.16
52-Week Range:
$7.80
$22.68
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Name
Bicara Therapeutics Inc
Sector
Industry
Phone
617-468-4219
Address
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
18.04 | 886.37M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| May-23-25 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Apr-17-25 | Initiated | Wells Fargo | Underweight |
| Feb-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
| Oct-08-24 | Initiated | Stifel | Buy |
| Oct-08-24 | Initiated | TD Cowen | Buy |
View All
Bicara Therapeutics Inc Stock (BCAX) Latest News
How Bicara Therapeutics Inc. stock reacts to job market data2025 Price Targets & Safe Entry Momentum Stock Tips - newser.com
Is Bicara Therapeutics Inc. stock safe for conservative investors - newser.com
Why Bicara Therapeutics Inc. stock appeals to analysts2025 Breakouts & Breakdowns & Reliable Momentum Entry Alerts - newser.com
What risks investors should watch in Bicara Therapeutics Inc. stock2025 EndofYear Setup & Consistent Income Trade Recommendations - newser.com
Should I hold or sell Bicara Therapeutics Inc. stock in 2025Insider Buying & Reliable Momentum Entry Alerts - newser.com
What dividend safety score for Bicara Therapeutics Inc. stockWall Street Watch & Long-Term Capital Growth Strategies - newser.com
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $29.67 Average Price Target from Analysts - Defense World
Analyzing Bicara Therapeutics Inc. with risk reward ratio chartsTrade Volume Report & High Conviction Buy Zone Picks - newser.com
Taking the lead: Bicara Therapeutics Inc (BCAX) - Setenews
How currency fluctuations impact Bicara Therapeutics Inc. stock2025 Market WrapUp & Accurate Buy Signal Alerts - newser.com
How to manage a losing position in Bicara Therapeutics Inc.Market Activity Summary & Fast Gain Swing Alerts - newser.com
How institutional buying supports Bicara Therapeutics Inc. stock2025 Geopolitical Influence & Capital Protection Trading Alerts - newser.com
Is Bicara Therapeutics Inc. stock resilient to inflationQuarterly Earnings Summary & Daily Technical Forecast Reports - newser.com
What institutional flow reveals about Bicara Therapeutics Inc.Weekly Market Report & Weekly High Conviction Trade Ideas - newser.com
Will a bounce in Bicara Therapeutics Inc. offer an exitTreasury Yields & AI Powered Market Entry Strategies - newser.com
Bicara Therapeutics (NASDAQ:BCAX) Earns “Outperform” Rating from Wedbush - Defense World
Wedbush Has Bearish Estimate for BCAX FY2025 Earnings - Defense World
How Bicara Therapeutics Inc. stock benefits from global expansion2025 Earnings Impact & Community Verified Swing Trade Signals - newser.com
Real time alert setup for Bicara Therapeutics Inc. performance2025 Technical Patterns & Low Drawdown Investment Ideas - newser.com
Wells Fargo Maintains Bicara Therapeutics (BCAX) Equal-Weight Recommendation - Nasdaq
An analyst sees good growth prospects for Bicara Therapeutics Inc (BCAX) - Setenews
HC Wainwright & Co. Initiates Coverage of Bicara Therapeutics (BCAX) with Buy Recommendation - MSN
Bicara Therapeutics Inc Stock (BCAX) Financials Data
There is no financial data for Bicara Therapeutics Inc (BCAX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):